Pharmacoeconomic analysis of maintenance treatment in bronchial asthma
https://doi.org/10.18093/0869-0189-2008-0-4-67-72
Abstract
Uncontrolled course of asthma leads to ineffective consumption of healthcare resources and increase in indirect costs due to work-off days, disability and increased mortality. The aim of this pharmacoeconomic study was economic substantiation of maintenance treatment in asthma. Pharmacoecomonic analysis was performed retrospectively using data of clinical and population-based trial, monitoring of drug prices and sales, law papers. Maximal rate of achievement of long-term asthma control was 75 % (according to the GOAL study), the mean cost of medications for asthma treatment was 16,006.42 rubles per 1 patients per a year. Length of inpatient stay, calls for emergency service, unscheduled visits to a doctor and work-off days were 22.88; 4.46; 2.28; and 22.80 vs. 0.136; 0; 0.08; and 0.008 in uncontrolled and fully controlled asthma, respectively. The costs provided by unscheduled consumption of healthcare resources were 37,872 and 12223.73 rubles per 1 patient per a year, respectively. The total cost was 25,642.25 rubles per 1 patient per a year under use of maintenance treatment and 37,872.12 rubles per 1 patient per a year without the maintenance therapy. Therefore, the saving effect was 12,230 rubles. In conclusion, maintenance treatment for achieving the full asthma control is economically reasonable and well-founded.
About the Authors
I. V. Demko
Кафедра внутренних болезней ФГУ "Красноярская государственная медицинская академия Министерства здравоохранения и социального развития России"
Russian Federation
Russian Federation
A. G. Tolkushin
ЗАО "ГлаксоСмитКляйн Трейдинг"
Russian Federation
Russian Federation
S. N. Kozlov
Кафедра клинической фармакологии ФГУ "Смоленская государственная медицинская академия Министерства здравоохранения и социального развития России"
Russian Federation
Russian Federation
A. G. Chuchalin
ФГУ НИИ пульмонологии ФМБА России
Russian Federation
Russian Federation
References
1. Masoli M., Fabian D., Holt S. et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–478.
2. Чучалин А.Г. Пульмонология в России и пути ее развития. Пульмонология 1998; 8 (4): 6–22.
3. Геппе Н.А. Современные представления о тактике лечения бронхиальной астмы у детей. Рус. мед. журн. 2002; 10 (7): 353–358.
4. Григорьева Н.О. Качество жизни и инвалидизация больных бронхиальной астмой. Вестн. СПбГМА им. И.И.Мечникова. 2006; 3: 23–27.
5. Демко И.В. Оптимизация диагностических и лечебных программ для больных бронхиальной астмой на модели крупного промышленного города: Дис. … д-ра мед. наук. М.; 2007.
6. Bateman E.D., Hurd S.S., Barnes P.J. et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 2008; 31: 143–178.
7. Bateman E.D., Bousquet J., Keech M.L. et al. The correlation between asthma control and health status: the GOAL study. Eur. Respir. J. 2007; 29: 56–62.
8. Bateman E.D. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.
9. Johanesson G., Andreasson E.B., Larsson P.E., Volgelmeier C.F. Cost-effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006; 24 (7): 695–708.
10. Rabe K.F., Atienza T., Magyar P. et al. Reduction of asthma exacerbations with budesonude in combination with formoterol for reliever therapy: a double-blind study. Lancet 2006; 368: 744–753.
11. Rabe K.F., Atienza T., Magyar P. et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized, controlled, double-blind study. Lancet 2006; 368: 744–753.
12. Rabe K.F., Pizzichini E., Ställberg B. et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129 (2): 246–256.
13. Vogelmeier C., D'Urzo A., Pauwels R. et al. Budesonide / formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J. 2005; 26 (5): 819–828.
14. Постановление Правительства РФ от 15 мая 2007 г. № 286 "О программе государственных гарантий оказания гражданам Российской Федерации бесплатной медицинской помощи на 2008 год". М.; 2007.
15. Федеральный закон от 29 дек. 2006 г. № 255-ФЗ "Об обеспечении пособиями по временной нетрудоспособности, по беременности и родам граждан, подлежащих обязательному социальному страхованию". М.; 2006.
Review
For citations:
Demko I.V., Tolkushin A.G., Kozlov S.N., Chuchalin A.G. Pharmacoeconomic analysis of maintenance treatment in bronchial asthma. PULMONOLOGIYA. 2008;(4):67-72. (In Russ.) https://doi.org/10.18093/0869-0189-2008-0-4-67-72
Views:
250
Email this article 